SAREPTA THERAPEUTICS
Sarepta Therapeutics is a biopharmaceutical company that focuses on the discovery and development of precision genetic medicine to treat rare diseases. It specializes in gene therapy, RNA-targeted exon skipping, and gene editing. It was founded in 1980 and headquartered in Cambridge, Massachusetts.
SAREPTA THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
1980-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.sarepta.com
Total Employee:
501+
Status:
Active
Contact:
5417543545
Total Funding:
1.38 B USD
Technology used in webpage:
SPF Domain Not Resolving Amazon Microsoft Azure DNS Amazon Virginia Region DMARC Mimecast ASP.NET 2.0 Symantec.cloud EasyDNS
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Corvidia
Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
Horizon Pharma
Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Douglas S Ingram CEO & President @ Sarepta Therapeutics
CEO & President
2017-07-01
Sandy Mahatme Chief Financial Officer, Chief Business Officer @ Sarepta Therapeutics
Chief Financial Officer, Chief Business Officer
2012-11-01
Jayant Aphale Senior Vice President of Technical Operations @ Sarepta Therapeutics
Senior Vice President of Technical Operations
Alex Lagadinos Associate Director, Corporate Development @ Sarepta Therapeutics
Associate Director, Corporate Development
2020-02-01
James Summerton Founder @ Sarepta Therapeutics
Founder
Kathy Behrens Wilsey Director @ Sarepta Therapeutics
Director
2009-03-01
Gary Charbonneau SVP, GM , Head of Research & Early Development @ Sarepta Therapeutics
SVP, GM , Head of Research & Early Development
2021-02-01
William (Bill) F. Ciambrone Executive Vice President, Technical Operations @ Sarepta Therapeutics
Executive Vice President, Technical Operations
2019-11-01
Gilmore O'Neill Executive Vice President, R&D & Chief Medical Officer @ Sarepta Therapeutics
Executive Vice President, R&D & Chief Medical Officer
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-02-27 | Myonexus Therapeutics | Myonexus Therapeutics acquired by Sarepta Therapeutics | 165 M USD |
| 2014-07-07 | Eisai | Eisai acquired by Sarepta Therapeutics | 25 M USD |
| 2008-03-12 | Ercole Biotech | Ercole Biotech acquired by Sarepta Therapeutics | N/A |
Investors List
Roche Financial
Roche Financial investment in Post-IPO Equity - Sarepta Therapeutics
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - Sarepta Therapeutics
MidCap Financial
MidCap Financial investment in Post-IPO Debt - Sarepta Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-03-16 | StrideBio | Sarepta Therapeutics investment in Series B - StrideBio | 81.5 M USD |
| 2020-10-22 | AavantiBio | Sarepta Therapeutics investment in Series A - AavantiBio | 107 M USD |
| 2018-08-09 | Lacerta Therapeutics | Sarepta Therapeutics investment in Venture Round - Lacerta Therapeutics | 30 M USD |
| 2018-05-08 | Myonexus Therapeutics | Sarepta Therapeutics investment in Corporate Round - Myonexus Therapeutics | 60 M USD |
Official Site Inspections
http://www.sarepta.com Semrush global rank: 1.15 M Semrush visits lastest month: 27.55 K
- Host name: ec2-54-204-43-126.compute-1.amazonaws.com
- IP address: 54.204.43.126
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Sarepta Therapeutics"
Meet Our Leadership | Sarepta Therapeutics
"Our strong culture is dependent upon the talented and passionate people who join Sarepta, are dedicated to our mission, and make a direct impact on the future of science. We are …See details»
Corporate Responsibility - Sarepta Therapeutics
At Sarepta, we strive to foster an environment where everyone can thrive. Workplace Demographics. Our employee demographics are included below, which reflect our …See details»
Sarepta Therapeutics - Wikipedia
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States.Incorporated in …See details»
Sarepta Therapeutics - Crunchbase Company Profile
Sarepta Therapeutics develops gene therapies aimed at treating Duchenne muscular dystrophy by delivering functional copies of the dystrophin gene to …See details»
Welcome to SareptAcademy | Sareptacademy
Welcome to SareptAcademy A COMMUNITY RESOURCE CENTER. At Sarepta, we are committed to a patients-come-first approach. We are working directly with people living with …See details»
Investor Relations | Sarepta Therapeutics, Inc.
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. We hold leadership positions …See details»
Sarepta Therapeutics - The Org
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.See details»
Sarepta Therapeutics Mission, Benefits, and Work Culture - Indeed
Themed monthly 'mingles' hosted by functional groups across the organization; Employee Assistance Program (EAP) Work-Life Events to support employees as they integrate home …See details»
Sarepta Therapeutics - Funding, Financials, Valuation & Investors
Aug 28, 2020 Sarepta Therapeutics 's most notable exits include LEXEO Therapeutics, Arrowhead Pharmaceuticals, and AavantiBio. Sarepta Therapeutics has acquired 3 …See details»
Sarepta Therapeutics Announces Global Licensing and …
Nov 26, 2024 He has led Sarepta as they advanced multiple investigational medicines through the clinical and regulatory process, built a commercial organization from the ground up, …See details»
About Our Company - Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We’re ushering in a new …See details»
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full …
Jan 13, 2025 Sarepta’s net product revenue does not include collaboration, contract manufacturing or royalty revenue. Fourth quarter and full-year 2024 net product revenue for …See details»
Sarepta Therapeutics - Contacts, Employees, Board Members, …
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases. ... Experience the new Crunchbase, powered by AI . Experience the new …See details»
Sarepta’s Duchenne Gene Therapy Placed on Hold in Europe
3 days ago The European Medicines Agency has requested that Sarepta Therapeutics and partner Roche pause a trio of clinical trials of their Duchenne muscular dystrophy gene therapy …See details»
Sarepta Dives On 'Another Unfortunate Development'
4 days ago Sarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold after a U.S. teenager died following treatment.See details»
Sarepta halts three studies testing gene therapy for muscle disorder
3 days ago April 4 (Reuters) - Sarepta Therapeutics (SRPT.O), opens new tab said on Friday it would temporarily halt three trials testing its gene therapy Elevidys. Last month, the company …See details»
Sarepta Therapeutics Announces Inducement Grants Under …
6 days ago CAMBRIDGE, Mass., March 31, 2025--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, …See details»
Sarepta, Roche halt 3 trials in Europe of gene therapy Elevidys
3 days ago The paused trials include the Sarepta-sponsored phase 3 Envision study, which is evaluating Elevidys in boys aged 8 to 17; Roche’s phase 2 Envol study, which is investigating …See details»
About Our Company | Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We’re ushering in a new …See details»
Learn how Sarepta takes a unique approach to find new …
Sarepta is using the tools of molecular biology to develop a variety of investigational products in the areas of gene therapy, RNA technology, and gene editing. We are continually seeking new …See details»